Ocuphire Pharma (OCUP)
(Delayed Data from NSDQ)
$1.39 USD
-0.07 (-4.47%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.38 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Income Statements
Fiscal Year end for Ocuphire Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 19 | 40 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 19 | 40 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 30 | 22 | 23 | 20 | 11 |
Income After Depreciation & Amortization | -11 | 18 | -23 | -20 | -11 |
Non-Operating Income | 1 | 0 | -34 | 2 | 3 |
Interest Expense | 0 | 0 | 0 | 7 | 0 |
Pretax Income | -10 | 18 | -57 | -25 | -9 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -10 | 18 | -57 | -25 | -9 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -10 | 18 | -57 | -25 | -9 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -11 | 18 | -23 | -20 | -11 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -11 | 18 | -23 | -20 | -11 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 21.59 | 20.60 | 14.85 | 4.66 | NA |
Diluted EPS Before Non-Recurring Items | -0.46 | 0.87 | -0.72 | -5.28 | NA |
Diluted Net EPS (GAAP) | -0.46 | 0.87 | -3.82 | -5.28 | -8.72 |
Fiscal Year end for Ocuphire Pharma, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.11 | 1.71 | 1.69 | 11.94 | 3.67 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.11 | 1.71 | 1.69 | 11.94 | 3.67 |
SG&A, R&D, and Dept/Amort Expenses | 9.44 | 9.42 | 7.12 | 5.55 | 9.06 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.33 | -7.71 | -5.43 | 6.39 | -5.39 |
Non-Operating Income | 0.56 | 0.60 | 0.63 | -0.81 | 0.43 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -7.77 | -7.11 | -4.80 | 5.58 | -4.96 |
Income Taxes | 0.00 | -7.11 | 0.00 | 0.01 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.77 | -7.11 | -4.80 | 5.56 | -4.96 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.77 | -7.11 | -4.80 | 5.56 | -4.96 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 25.83 | 24.52 | 22.99 | 22.41 | 20.96 |
Diluted EPS Before Non-Recurring Items | -0.30 | -0.29 | -0.21 | 0.25 | -0.24 |
Diluted Net EPS (GAAP) | -0.30 | -0.29 | -0.19 | 0.25 | -0.24 |